BijalDineshShahMD

Hematologic Oncology

Physician

Overview of Dr. Shah

Dr. Bijal Shah is an oncologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. He received his medical degree from University of South Florida Morsani College of Medicine and has been in practice 13 years. He is one of 170 doctors at H. Lee Moffitt Cancer Center and Research Institute who specialize in Oncology. He has more than 100 publications and over 500 citings.

Office
12902 Magnolia Dr
CSB 7
Tampa, FL 33612
Book by Phone+1(929) 590-5016

Education & Training

Duke University HospitalResidency, Internal Medicine/Pediatrics, 2004 - 2008
University of South Florida College of MedicineClass of 2004

Certifications & Licensure

FL State Medical License 2008 - 2025
NC State Medical License 2004 - 2008
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL Start of enrollment: 2012 Mar 30
Active, not recruiting
Phase 2
A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib Start of enrollment: 2013 Feb 20
Completed
Phase 1, Phase 2
A Safety Study of SGN-CD19A for Leukemia and Lymphoma Start of enrollment: 2013 Feb 01
Completed
Phase 1
A Safety Study of SGN-CD19A for B-Cell Lymphoma Start of enrollment: 2013 Feb 01
Completed
Phase 1
Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30 Start of enrollment: 2014 Apr 01
Terminated
Not Applicable
Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS) Start of enrollment: 2013 Aug 29
Completed
Phase 2
ACY-1215 for Relapsed/Refractory Lymphoid Malignancies Start of enrollment: 2014 Apr 02
Completed
Phase 1, Phase 2
Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma Start of enrollment: 2014 Sep 23
Completed
Phase 1, Phase 2
Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia Start of enrollment: 2018 Oct 11
Completed
Phase 2
Blincyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphi CD19+ ALL Start of enrollment: 2022 Jan 01
Withdrawn
Phase 2
XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia Start of enrollment: 2022 Feb 02
Recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

26 citations
Neuroprotective Effects of Annexin A1 Tripeptide after Deep Hypothermic Circulatory Arrest in Rats.
Zhiquan Zhang, Qing Ma, Bijal D. Shah, G. Burkhard Mackensen, Donald C. Lo
Frontiers in Immunology. 2017-08-30
17 citations
Impact of Total Body Irradiation-Based Myeloablative Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell ...
Farhad Khimani, Mudit Dutta, Rawan Faramand, Taiga Nishihori, Ariel Perez Perez
Transplantation and Cellular Therapy. 2021-07-01
32 citations
The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis.
Armin Ghobadi, Michael Slade, Hagop Kantarjian, Julio Alvarenga, Ibrahim Aldoss
Blood. 2022-11-17

Abstracts/Posters

The Lymphoma Tumor Microenvironment Influences Toxicity after CD19 CAR T Cell Therapy
Bijal Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Impact of Interim FDG-PET (iPET) in the Outcomes of Patients with Aggressive B-Cell Lymphomas Receiving DA-EPOCH-R
Bijal Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Moffitt Cancer Center 2-Year Single-Institution Experience with Next-Generation Sequencing Minimal Residual Disease Detection: Clinical Utility, Application, and Corre...
Bijal Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
AG-636 for the Treatment of Adults with Advanced Lymphoma: Initiation of a Phase 1 Clinical Study
Bijal Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Impact of TBI-Based Conditioning Regimen on Outcomes of Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplant: Systematic Revi...
Bijal Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Initial Findings of the Phase 1 Trial of PBCAR0191, a CD19 Targeted Allogeneic CAR-T Cell Therapy
Bijal Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Fever Characteristics Associated with Toxicity and Outcome after Anti-CD19 CAR T-Cell Therapy for Aggressive Lymphoma
Bijal Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Use of Lenalidomide Plus Rituximab in TP53-Mutated Mantle Cell Lymphoma (MCL) Outside of Clinic Trial: The Moffitt Experience
Bijal Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

End of phase I results of ZUMA-3, a phase 1/2 study of KTE-X19, anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in adult patients (pts) with relapsed/refract...
2019 ASCO Annual Meeting - 6/1/2019
A Phase II Study of Brentuximab Vedotin Plus Adriamycin and Dacarbazine without Radiation in Non-Bulky Limited Stage Classical Hodgkin Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Outcomes of patients (pts) treated with prior blinatumomab (Blin) in ZUMA-3: A study of KTE-C19, an anti-CD19 chimeric antigen receptor (CAR) t cell therapy, in adult ...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

Tecartus® Car T-cell Therapy Demonstrates Strong Overall Survival Rates and Continued Durable Responses in Long-Term Follow-up of Two Pivotal Studies Including Longest Ever Follow-up of a CAR T-cell Therapy in Mantle Cell LymphomaJune 4th, 2022
Kite’s Tecartus Is First CAR T Therapy Approved for Adults with B-cell ALLOctober 4th, 2021
$U.S. FDA Approves Kite’s Tecartus® as the First and Only Car T for Adults with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia$
U.S. FDA Approves Kite’s Tecartus® as the First and Only Car T for Adults with Relapsed or Refractory B-cell Acute Lymphoblastic LeukemiaOctober 2nd, 2021
Join now to see all